Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis

References

• Libby E, Garcia D, Quintana D, et al. Disease-specific survival for patients with multiple myeloma: significant improvements over time in all age groups. Leuk Lymphoma. 2014;55:2850–2857.
   PubMed Web of Science ®Google Scholar
• Velcade label-accessdata FDA [Internet]. 2008. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/02160-2s015lbl.pdf
   Google Scholar
• Groll M, Berkers CR, Ploegh HL, et al. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure. 2006;14:451–456.
   PubMed Web of Science ®Google Scholar
• Hasinoff BB, Patel D, Wu X. Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib. CardiovascToxicol. 2017;17:237--250.
   Google Scholar
• Kyprolis label-accessdata FDA [Internet]. 2015. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202714s009lbl.pdf
   Google Scholar
• Xiao Y, Yin J, Wei J, et al. Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis. PLoS One. 2014;9:e87671.
   PubMed Web of Science ®Google Scholar
• Tjionas H, Gupta AK. Heart failure secondary to carfilzomib-induced heart block in multiple myeloma patients. J Oncol Pharm Pract. 2017;23:152–156.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Gatt ME, Rouvio O, et al. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study. Br J Haematol. 2016;172:89–96.
   PubMed Web of Science ®Google Scholar
• Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98:1753–1761.
   PubMed Web of Science ®Google Scholar
• Moher DLA, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events criteria V4.0 (CTCAE) [Internet]. [cited 2018 Feb 15]. Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
   Google Scholar
• Higgins J, Green S. Cochrane handbook for systemic review of interventions. John Wiley and sons, New York NCC, 2008.
   Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.
   PubMed Web of Science ®Google Scholar
• Viechtbauer W. Conducting meta-analyses in R with the metaphor package. J Stat Soft. 2010;36:1–48.
   Web of Science ®Google Scholar
• Berdeja JG, Hart LL, Mace JR, et al. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. Haematologica. 2015;100:670–676.
   PubMed Web of Science ®Google Scholar
• Berenson JR, Hilger JD, Yellin O, et al. Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy. Leukemia. 2014;28:1529–1536.
   PubMed Web of Science ®Google Scholar
• Berenson J, Cartmell A, Lyons R, et al. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma). Blood. 2016;127:3360–3368.
   PubMed Web of Science ®Google Scholar
• Bringhen S, Petrucci MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014;124:63–69.
   PubMed Web of Science ®Google Scholar
• Bringhen S, Rossi D, Larocca A, et al. Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCyd) in Elderly Newly Diagnosed Multiple Myeloma Patients: Results of a Phase 2 Study. Blood. 2015;126:1828. (Abstract).
   Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27–38.
   PubMed Web of Science ®Google Scholar
• Forsberg PA, Rossi AC, Pearse RN, et al. Carfilzomib induction with lenalidomide and clarithromycin consolidation and lenalidomide maintenance (CarBiRD) for multiple myeloma (MM). Blood. 2016;128:4518. (Abstract).
   Web of Science ®Google Scholar
• Hajek R, Masszi T, Petrucci MT, et al. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017;31:107–114.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Vij R, Stewart K, et al. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia. 2012;12:310–318.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Dytfeld D, Jagannath S, et al. Final results of a frontline phase 1/2 study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in multiple myeloma (MM). Blood. 2011;118:288–289.
   Web of Science ®Google Scholar
• Korde N, Roschewski M, Zingone A, et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 2015;1:746–754.
   PubMed Web of Science ®Google Scholar
• Lendvai N, Hilden P, Devlin S, et al. A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood. 2014;124:899–906.
   PubMed Web of Science ®Google Scholar
• Badros AZ, Vij R, Martin T, et al. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia. 2013;27:1707–1714. doi:10.1038/leu.2013.29.
   PubMed Web of Science ®Google Scholar
• Mark TM, Yadlapati S, Neglyad L, et al. High-dose carfilzomib and dexamethasone as first-line treatment in symptomatic multiple myeloma. Blood. 2015;126:4258. (Abstract).
   Web of Science ®Google Scholar
• Mikhael JR, Reeder CB, Libby EN, et al. Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma. Br J Haematol. 2015;169:219–227.
   PubMed Web of Science ®Google Scholar
• Moreau P, Kolb B, Attal M, et al. Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. Blood. 2015;125:3100–3104.
   PubMed Web of Science ®Google Scholar
• Papadopoulos KP, Burris HA, Gordon M, et al. A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013;72:861–868.
   PubMed Web of Science ®Google Scholar
• Pawlyn C, Davies F, Cairns D, et al. The quadruplet KCRD (carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone) is safe and well tolerated as induction therapy for newly diagnosed, transplant eligible, myeloma patients. Clinical Lymphoma, Myeloma Leukemia. 2015;15:e50. (Abstract BP-012).
   Google Scholar
• Roussel M, Lauwers-Cances V, Robillard N, et al. Frontline therapy with carfilzomib, lenalidomide, and dexamethasone (KRd) induction followed by autologous stem cell transplantation, Krd consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma (NDMM) patients: primary results of the intergroupe Francophone Du MyéLome (IFM) Krd Phase II Study. Blood. 2016;128:1142. (Abstract).
   Web of Science ®Google Scholar
• Siegel DS, Berdeja JG, Infante JR, et al. Updated results from a phase 2 extension study of patients with multiple myeloma or solid tumors previously enrolled in carfilzomib company-sponsored phase 1 and 2 clinical trials (PX-171-010). Blood. 2014;124:2134. (Abstract).
   Web of Science ®Google Scholar
• Siegel D, Martin T, Wang M, et al. A phase ll study (PX-171-003-A1) of single-agent carfilzomib in patients with advanced relapsed and refractory multiple myeloma. Onkologie. 2013;36:38–39.
   Google Scholar
• Sonneveld P, Asselbergs E, Zweegman S, et al. Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. Blood [Internet]. 2015;125:449–456.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142–152.
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab and dexamethasone (CaRD) is highly active and offers a neuropathy sparing approach for proteasome-inhibitor based therapy in Waldenstrom's macroglobulinemia. Blood. 2014;124:503–510.
   PubMed Web of Science ®Google Scholar
• Vij R, Siegel DS, Jagannath S, et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012;158:739–748.
   PubMed Web of Science ®Google Scholar
• Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012;119:5661–5670.
   PubMed Web of Science ®Google Scholar
• Wang M, Martin T, Bensinger W, et al. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood. 2013;122:3122–3128.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Tobinai K, Matsumoto M, et al. A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma. Br J Haematol. 2016;172:745–756.
   PubMed Web of Science ®Google Scholar
• Yong KL, Brown S, Hinsley S, et al. Carfilzomib, cyclophosphamide and dexamethasone is well tolerated in patients with relapsed/refractory multiple myeloma who have received one prior regimen. Blood. 2015;126:1840. (Abstract).
   Web of Science ®Google Scholar
• Wei Q, Xia Y. Proteasome inhibition down-regulates endothelial nitric-oxide synthase phosphorylation and function. J Biol Chem. 2006;281:21652–21659.
   PubMed Web of Science ®Google Scholar
• Meiners S, Ludwig A, Stangl V, et al. Proteasome inhibitors: poisons and remedies. Med Res Rev. 2008;28:309–327.
   PubMed Web of Science ®Google Scholar
• Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am CollCardiol. 2009;53:2231–2247.
   Web of Science ®Google Scholar
• Shiojima I, Sato K, Izumiya Y, et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest. 2005;115:2108–2118.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Roussou M, Gavriatopoulou M, et al. Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Adv. 2017;1:449–454.
   PubMed Web of Science ®Google Scholar
• Russell SD, Lyon A, Lenihan DJ, et al. Serial echocardiographic assessment of patients (Pts) with relapsed multiple myeloma (RMM) receiving carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd): a substudy of the phase 3 endeavor trial (NCT01568866). Blood. 2015;126:4250. (Abstract).
   Web of Science ®Google Scholar
• Shah C, Gong Y, Szady A, et al. Unanticipated cardiotoxicity associated with targeted anticancer therapy in patients with hematologic malignancies patients: natural history and risk factors. Cardiovasc Toxicol. 2017 [Oct 11]. DOI:10.1007/s12012-017-9429-8
   PubMed Web of Science ®Google Scholar